Erythropoietin and retinopathy of prematurity: a meta-analysis

European Journal of Pediatrics

Volumn 173, Issue 10, 2014, Pages 1355-1364

  Xu, Xu Juan ^a   Huang, Hai Yan ^a   Chen, Hong Lin ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Erythropoietin; Meta analysis; Preterm infant; Retinopathy of prematurity

Indexed keywords

ERYTHROPOIETIN; ANTIANEMIC AGENT;

ARTICLE; DATA BASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EFFECT SIZE; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; PREMATURITY; RETROLENTAL FIBROPLASIA; RISK FACTOR; CHEMICALLY INDUCED; NEWBORN; RISK; STATISTICAL MODEL;

ERYTHROPOIETIN; HEMATINICS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MODELS, STATISTICAL; ODDS RATIO; RETINOPATHY OF PREMATURITY;

EID: 84918796212     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-014-2332-4     Document Type: Article

References (31)

1. Aher SM, Ohlsson A (2012) Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 9, CD004868
2. Aher SM, Ohlsson A (2012) Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 10, CD004865
3. Autrata R, Senková K, Holousová M, Helmanová I, Pyrochtová S (2008) Combined treatment with laser photocoagulation and cryotherapy for threshold retinopathy of prematurity. Eur J Ophthalmol 18(1):112–117
4. Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q (2006) Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 72(1):51–59
5. Chen J, Smith LE (2007) Retinopathy of prematurity. Angiogenesis 10(2):133–140
6. Dame C, Juul SE, Christensen RD (2001) The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 79(3–4):228–235
7. Dani C, Reali MF, Bertini G, Martelli E, Pezzati M, Rubaltelli FF (2001) The role of blood transfusions and iron intake on retinopathy of prematurity. Early Hum Dev 62(1):57–63
8. Donato H, Vain N, Rendo P, Vivas N, Prudent L, Larguía M (2000) Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial. Pediatrics 105(5):1066–1072
9. Fauchère JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M (2008) An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 122(2):375–382
10. Figueras-Aloy J, Alvarez-Domínguez E, Morales-Ballus M, Salvia-Roiges MD, Moretones-Suñol G (2010) Early administration of erythropoietin in the extreme premature, a risk factor for retinopathy of prematurity? An Pediatr (Barc) 73(6):327–333
11. Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84(2):77–82
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
13. Jadad AR, Moore RA, Carroll D (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
14. Krantz SB (1991) Erythropoietin. Blood 77(3):419–434
15. Kumar P, Shankaran S, Krishnan RG (1998) Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double-blind, placebo-controlled trial. J Perinatol 18(3):173–177
16. Maier RF, Obladen M, Müller-Hansen I, Kattner E, Merz U, Arlettaz R (2002) Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr 141(1):8–15
17. Manzoni P, Maestri A, Gomirato G (2005) Erythropoietin as a retinal angiogenic factor. N Engl J Med 353(20):2190–2191
18. Mehmet S, Fusun A, Sebnem C, Ozgur O, Gulten E, Taylan OA (2011) One-year experience in the retinopathy of prematurity: frequency and risk factors, short-term results and follow-up. Int J Ophthalmol 4(6):634–640
19. Meyer MP, Meyer JH, Commerford A, Hann FM, Sive AA, Moller G (1994) Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study. Pediatrics 93(6 Pt 1):918–923
20. Ohls RK, Christensen RD, Kamath-Rayne BD, Rosenberg A, Wiedmeier SE, Roohi M (2013) A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants. Pediatrics 132(1):e119–e127
21. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ (2001) Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 108(4):934–942
22. Ohlsson A, Aher SM (2012) Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 9, CD004863
23. Romagnoli C, Zecca E, Gallini F, Girlando P, Zuppa AA (2000) Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity? Eur J Pediatr 159(8):627–628
24. Sato T, Kusaka S, Shimojo H, Fujikado T (2009) Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 116(9):1599–1603
25. Schneider JK, Gardner DK, Cordero L (2008) Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants. Pharmacotherapy 28(11):1335–1340
26. Shah N, Jadav P, Jean-Baptiste D, Weedon J, Cohen LM, Kim MR (2010) The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. Am J Perinatol 27(1):67–71
27. Shannon KM, Keith JF 3rd, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA (1995) Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 95(1):1–8
28. Suk KK, Dunbar JA, Liu A, Daher NS, Leng CK, Leng JK (2008) Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS 12(3):233–238
29. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M (2005) Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353(8):782–792
30. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Ottawa Health Research Institute. Available from: URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Assessed 20 Nov 2013
31. Zayed MA, Uppal A, Hartnett ME (2010) New-onset maternal gestational hypertension and risk of retinopathy of prematurity. Invest Ophthalmol Vis Sci 51(10):4983–4988